40 results on '"Lassen, Pernille"'
Search Results
2. CSF proteome in multiple sclerosis subtypes related to brain lesion transcriptomes
- Author
-
Elkjaer, Maria L., Nawrocki, Arkadiusz, Kacprowski, Tim, Lassen, Pernille, Simonsen, Anja Hviid, Marignier, Romain, Sejbaek, Tobias, Nielsen, Helle H., Wermuth, Lene, Rashid, Alyaa Yakut, Høgh, Peter, Sellebjerg, Finn, Reynolds, Richard, Baumbach, Jan, Larsen, Martin R., and Illes, Zsolt
- Published
- 2021
- Full Text
- View/download PDF
3. DAHANCA 10 – Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group
- Author
-
Overgaard, Jens, Hoff, Camilla Molich, Hansen, Hanne Sand, Specht, Lena, Overgaard, Marie, Lassen, Pernille, Andersen, Elo, Johansen, Jørgen, Andersen, Lisbeth Juhler, Evensen, Jan Folkvard, Alsner, Jan, and Grau, Cai
- Published
- 2018
- Full Text
- View/download PDF
4. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project
- Author
-
Lassen, Pernille, Lacas, Benjamin, Pignon, Jean-Pierre, Trotti, Andy, Zackrisson, Bjorn, Zhang, Qiang, Overgaard, Jens, and Blanchard, Pierre
- Published
- 2018
- Full Text
- View/download PDF
5. Understanding Alzheimer's disease by global quantification of protein phosphorylation and sialylated N-linked glycosylation profiles: A chance for new biomarkers in neuroproteomics?
- Author
-
Lassen, Pernille S., Thygesen, Camilla, Larsen, Martin R., and Kempf, Stefan J.
- Published
- 2017
- Full Text
- View/download PDF
6. Prevalence of medication-related falls in 200 consecutive elderly patients with hip fractures: a cross-sectional study
- Author
-
Andersen, Charlotte Uggerhøj, Lassen, Pernille Overgaard, Usman, Hussain Qassim, Albertsen, Nadja, Nielsen, Lars Peter, and Andersen, Stig
- Published
- 2020
- Full Text
- View/download PDF
7. HPV testing versus p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: results from the DAHANCA 19 study.
- Author
-
Lilja-Fischer, Jacob Kinggaard, Kristensen, Morten Horsholt, Lassen, Pernille, Steiniche, Torben, Tramm, Trine, Stougaard, Magnus, Maare, Christian, Johansen, Jørgen, Primdahl, Hanne, Kristensen, Claus Andrup, Andersen, Maria, Eriksen, Jesper Grau, and Overgaard, Jens
- Subjects
DNA analysis ,RESEARCH ,PAPILLOMAVIRUSES ,CONFIDENCE intervals ,IMMUNOHISTOCHEMISTRY ,LOG-rank test ,OROPHARYNGEAL cancer ,EARLY detection of cancer ,RANDOMIZED controlled trials ,CANCER patients ,PAPILLOMAVIRUS diseases ,RESEARCH funding ,DESCRIPTIVE statistics ,DATA analysis software ,SQUAMOUS cell carcinoma ,LONGITUDINAL method - Abstract
The prognosis after primary (chemo-)radiotherapy for oropharyngeal squamous cell carcinoma (OPSCC) is affected by Human Papillomavirus (HPV) status, with a better prognosis in HPV-positive OPSCC. HPV-status is routinely assessed by p16 immunohistochemistry (IHC), but additional HPV DNA testing is debated. Also, there are numerous HPV genotypes, which prognostic role may need clarification. The purpose of this study was: (1) to test a custom-made targeted HPV next generation sequencing (NGS) panel in OPSCC, (2) to determine correlation with p16 IHC, and (3) to assess the impact of HPV DNA testing on outcome in the prospectively randomized clinical trial DAHANCA 19. We included 271 patients with OPSCC treated with primary (chemo-)radiotherapy in the DAHANCA 19 trial. Of these, 199 (73%) were p16-positive. HPV-status was determined by targeted HPV next generation sequencing (NGS), using a custom-made HPV genotyping panel. HPV was detected in 194 tumor samples. p16 IHC and NGS HPV status were concordant in 265 (98%) of 271 patients, whereas we did not detect HPV DNA in 5 p16-positive tumors. HPV16 accounted for 169 of 194 HPV-positive cases (87%). HPV genotypes 18, 31, 33, 35, and 59 were also detected. Loco-regional failure and overall survival were similar whether patients were separated by p16 IHC, or HPV DNA status (p < 0.0001 for all) and did not depend on HPV genotype (p = 0.9 and p = 0.7). In the present study, HPV DNA testing or typing in a Danish OPSCC cohort did not add additional information to p16 IHC, the most widely used and accepted prognostic indicator. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Socioeconomic position and the pre-diagnostic interval among patients diagnosed with head and neck squamous cell carcinoma - a population-based study from DAHANCA.
- Author
-
Halgren Olsen, Maja, Maltesen, Thomas, Lassen, Pernille, Kjaer, Trille Kristina, Johansen, Jørgen, Primdahl, Hanne, Andersen, Elo, Kristensen, Claus Andrup, Andersen, Maria, Farhadi, Mohammad, Overgaard, Jens, and Dalton, Susanne Oksbjerg
- Subjects
HEAD & neck cancer diagnosis ,CONFIDENCE intervals ,SELF-evaluation ,HEAD & neck cancer ,TUMOR classification ,SOCIOECONOMIC factors ,CANCER patients ,RESEARCH funding ,DESCRIPTIVE statistics ,MEDICAL referrals ,LOGISTIC regression analysis ,ODDS ratio ,SQUAMOUS cell carcinoma ,COMORBIDITY ,SECONDARY analysis ,SYMPTOMS - Abstract
The socioeconomic differences in survival are pronounced for patients diagnosed with head and neck cancer; disease stage at diagnosis is suggested to be a main driver of this association. This nationwide, population-based study investigates socioeconomic differences in the pre-diagnostic interval and disease stage at diagnosis. Information on patient-reported symptoms, symptom onset and disease-specific factors was obtained from the nationwide population-based Danish Head and Neck Cancer Group (DAHANCA) database for patients diagnosed with head and neck squamous cell carcinoma between 2008 and 2019 in Denmark. Socioeconomic position (SEP) was measured by individual-level education, income and cohabitation status obtained from administrative registers. Socioeconomic differences in the interval from symptom onset to diagnosis were investigated in general linear models with 95% confidence intervals (CIs); overall and by subsite, symptom and comorbidity score. Consultation patterns prior to diagnosis were examined using methods for change-point detection. Associations with advanced-stage disease were estimated in logistic regression models. Patients with low, medium and high SEP had a similar interval from patient-reported symptom onset to diagnosis of 10 weeks. Although this interval varied according to primary symptom and anatomical subsite, no apparent socioeconomic differences were observed within these subgroups. Aligned with the patient-reported symptom onset, a distinct increase in consultation rates was observed at 9 weeks (95% CI [7.3; 10.7]) for patients with low SEP and 7 weeks (95% CI [4.8; 9.2]) for patients with high SEP, with overlapping CIs. Patients with low compared to high SEP had increased odds for advanced-stage glottic and oral cavity squamous cell carcinoma. For the remaining subsites the association varied according to SEP-indicator and TNM-edition. The interval from symptom onset to diagnosis and consultation patterns were similar across SEP groups. Still, socioeconomic differences in stage at diagnosis were observed for some – but not all – subsites. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Fever of Unknown Origin: A Validation Study of Danish ICD-10 Diagnosis Codes
- Author
-
Gedebjerg, Anne, Kirk, Karina Frahm, Lassen, Pernille Overgaard, Farkas, Dóra K, and Søgaard, Kirstine K
- Subjects
Epidemiology ,fever of unknown origin ,positive predictive value ,Clinical Epidemiology ,validation studies - Abstract
Anne Gedebjerg,1 Karina Frahm Kirk,2 Pernille Overgaard Lassen,3 Dóra K Farkas,4 Kirstine K Søgaard1,4,5 1Department of Clinical Microbiology, Aalborg University Hospital, Aalborg, Denmark; 2Department of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark; 3Department of Clinical Medicine, North Denmark Regional Hospital, Hjørring, Denmark; 4Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark; 5Department of Clinical Medicine, Aalborg University, Aalborg, DenmarkCorrespondence: Kirstine K Søgaard, Department of Clinical Microbiology, Aalborg University Hospital, Aalborg, Denmark, Email kirstine.soegaard@rn.dkBackground: Real-world data in form of routinely collected clinical data are a valuable resource for epidemiological research in infectious disease. We examined the validity of a discharge diagnosis of fever of unknown origin from hospital discharge registries.Methods: We identified patients with a first in- or outpatient diagnosis (primary or secondary) of fever of unknown origin (ICD-10 code R50.0; R50.8, R50.9) recorded in the Danish National Patient Registry (DNPR) between 2010 and 2017 in the North Denmark Region. We based the validation cohort on a mix of patients diagnosed at a highly specialized university department of infectious diseases (n=100), other internal medicine departments (n=50), and patients diagnosed at a regional non-university hospital (n=50). We estimate positive predictive value (PPV) of diagnosis for fever of unknown origin using medical records as reference.Results: The PPV of a diagnosis of fever of unknown origin for patients diagnosed at the infectious disease department was 61% (95% CI: 51â 71%). For other internal medicine departments, it was 14% (95% CI: 6â 27%), and for the non-university hospital it was 16% (95% CI: 7â 29%). To achieve higher PPVs, we excluded immunocompromised patients, patients who were diagnosed with infection, cancer or rheumatic disease within 7 days after admission, and/or patients with a short hospital stay (maximum 3 days) and no subsequent hospital contact within 1 month. The PPV for diagnoses from the Department of Infectious Diseases improved to 82% (95% CI: 68â 91%) for other internal medicine departments it improved to 31% (95% CI: 11â 59%), and for the non-university hospital it improved to 36% (95% CI: 13â 65%).Conclusion: We found that only diagnoses made in the Department of Infectious Diseases accurately identified fever of unknown origin, whereas diagnoses made in other units mainly covered infection-related fever, cancer-related fever, or short unspecific fever without further diagnostic work-up.Keywords: fever of unknown origin, positive predictive value, validation studies
- Published
- 2022
10. Association of Smoking, Comorbidity, Clinical Stage, and Treatment Intent With Socioeconomic Differences in Survival After Oropharyngeal Squamous Cell Carcinoma in Denmark
- Author
-
Olsen, Maja Halgren, Frederiksen, Kirsten, Lassen, Pernille, Rotbøl, Charlotte, Kjaer, Trille Kristina, Johansen, Jørgen, Primdahl, Hanne, Andersen, Elo, Kristensen, Claus Andrup, Andersen, Maria, Farhadi, Mohammad, Overgaard, Jens, and Dalton, Susanne Oksbjerg
- Subjects
Aged, 80 and over ,Cohort Studies ,Squamous Cell Carcinoma of Head and Neck ,Head and Neck Neoplasms ,Smoking ,Papillomavirus Infections ,Humans ,Female ,General Medicine ,Smoking/epidemiology ,Middle Aged - Abstract
ImportanceThe socioeconomic gap in survival after cancer is pronounced among patients with head and neck cancer. Understanding the mechanisms of this gap is crucial to target intervention strategies.ObjectiveTo investigate socioeconomic differences in survival after oropharyngeal squamous cell carcinoma (OPSCC) according to human papillomavirus (HPV) status and the extent to which smoking, comorbidity, clinical stage, and treatment intent explain the survival gap.Design, Setting, and ParticipantsThis nationwide, population-based cohort study was based on prospectively collected information on all patients with a diagnosis of OPSCC from the Danish Head and Neck Cancer Group database and administrative registries. The study included 4600 patients born in 1921 or later, aged 30 years or older, and residing in Denmark 1 year prior to OPSCC diagnosis. Patients with missing information (547 [12%]) were excluded. Patients were diagnosed between January 1, 2008, and December 31, 2019, and followed up until December 31, 2021. Data were analyzed from June 6 to October 4, 2022.ExposureSocioeconomic position (educational level, disposable income, or cohabiting status).Main Outcomes and MeasuresSocioeconomic differences in 5-year overall survival were estimated in Cox proportional hazards regression models by HPV status. The indirect effect and proportion mediated by smoking, comorbidity, clinical stage, and treatment intent were estimated based on a counterfactual approach.ResultsThe analyzed cohort comprised 4053 patients (1045 women [26%] and 3008 men [74%]). The median age was 61 years (IQR, 55-68 years), and 2563 patients (63%) had HPV-positive OPSCC while 1490 patients (37%) had HPV-negative OPSCC. The 5-year standardized overall survival was 10% to 15% lower among patients with a lower educational level, with low disposable income, or who were living alone (patients with HPV-positive OPSCC, 68%-71%; patients with HPV-negative OPSCC, 31%-34%) than patients with a higher educational level, high disposable income, or a cohabiting partner (patients with HPV-positive OPSCC, 81%-86%; patients with HPV-negative OPSCC, 43%-46%). Among patients with HPV-positive OPSCC, a considerable part of this survival gap was estimated to be associated with differences in smoking (27%-48%), comorbidity (10%-19%), clinical stage (8%-19%), and treatment intent (16%-28%). Among those with HPV-negative OPSCC, comorbidity (12%-22%) and treatment intent (16%-42%) were the primary potential mediators.Conclusions and RelevanceThis cohort study suggests that, regardless of HPV status, patients with low socioeconomic position had 10% to 15% lower 5-year overall survival than patients with high socioeconomic position. A substantial part of this survival gap was associated with differences in smoking, comorbidity, clinical stage, or treatment intent at diagnosis.
- Published
- 2022
11. Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer
- Author
-
Lassen, Pernille, Primdahl, Hanne, Johansen, Jørgen, Kristensen, Claus A., Andersen, Elo, Andersen, Lisbeth J., Evensen, Jan F., Eriksen, Jesper G., and Overgaard, Jens
- Published
- 2014
- Full Text
- View/download PDF
12. Expression of EGFR and HPV-associated p16 in oropharyngeal carcinoma: Correlation and influence on prognosis after radiotherapy in the randomized DAHANCA 5 and 7 trials
- Author
-
Lassen, Pernille, Overgaard, Jens, and Eriksen, Jesper Grau
- Published
- 2013
- Full Text
- View/download PDF
13. Laparoscopic surgery for early endometrial cancer
- Author
-
Bennich, Gitte, Rudnicki, Martin, and Lassen, Pernille D.
- Published
- 2016
- Full Text
- View/download PDF
14. The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome
- Author
-
Lassen, Pernille
- Published
- 2010
- Full Text
- View/download PDF
15. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer
- Author
-
Lassen, Pernille, Eriksen, Jesper Grau, Hamilton-Dutoit, Stephen, Tramm, Trine, Alsner, Jan, and Overgaard, Jens
- Published
- 2010
- Full Text
- View/download PDF
16. Treatment outcomes and survival following definitive (chemo)radiotherapy in HPV‐positive oropharynx cancer: Large‐scale comparison of DAHANCA vs PMH cohorts.
- Author
-
Lassen, Pernille, Huang, Shao Hui, Su, Jie, Waldron, John, Andersen, Maria, Primdahl, Hanne, Johansen, Jørgen, Kristensen, Claus Andrup, Andersen, Elo, Eriksen, Jesper Grau, Hansen, Christian Rønn, Alsner, Jan, Lilja‐Fisher, Jacob, Bratman, Scott V., Ringash, Jolie, Kim, John, Hope, Andrew, Spreafico, Anna, de Almeida, John, and Xu, Wei
- Subjects
OROPHARYNX ,TREATMENT effectiveness ,SURVIVAL rate ,RADIOTHERAPY ,PROGNOSIS - Abstract
We compare outcomes in two large‐scale contemporaneously treated HPV‐positive (HPV+) oropharynx cancer (OPC) cohorts treated with definitive radiotherapy/chemoradiotherapy (RT/CRT). p16‐confirmed HPV+ OPC treated between 2007 and 2015 at PMH and DAHANCA were identified. Locoregional failure (LRF), distant metastasis (DM), and overall survival (OS) were compared. Multivariable analysis (MVA) calculated adjusted‐hazard‐ratio (aHR) with 95% confidence interval (95% CI), adjusting for cohort, age, gender, performance status, smoking pack‐years, T‐category and N‐category and chemotherapy. Compared to PMH (n = 701), DAHANCA (n = 1174) contained lower TNM‐8T‐categories (T1‐T2: 77% vs 56%), N‐categories (N0‐N1: 77% vs 67%) and stages (stage I: 63% vs 44% (all P <.001). PMH used standard‐fractionation CRT in 69% (481) while 31% (220) received hypofractionated or moderately accelerated RT‐alone. All DAHANCA patients were treated with moderately accelerated RT; 96% (1129) received nimorazole (NIM) and 73% (856) concurrent weekly cisplatin. DAHANCA had shorter overall‐treatment‐time (P <.001), lower gross tumor (66‐68 vs 70 Gy) and elective neck (50 vs 56 Gy) doses. Median follow‐up was 4.8 years. DAHANCA had higher 5‐year LRF (13% vs 7%, aHR = 0.47 [0.34‐0.67]), comparable DM (7% vs 12%, aHR = 1.32 [0.95‐1.82]), but better OS (85% vs 80%, aHR = 1.30 [1.01‐1.68]). CRT patients had a lower risk of LRF (aHR 0.56 [0.39‐0.82]), DM (aHR 0.70 [0.50‐1.00]) and death (aHR 0.39 [0.29‐0.52]) vs RT‐alone. We observed exemplary outcomes for two large‐scale trans‐Atlantic HPV+ OPC cohorts treated in a similar manner. Concurrent chemotherapy was a strong, independent prognostic factor for all endpoints. Our findings underscore the need for a very careful approach to de‐intensification of treatment for this disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Same-day discharge after laparoscopic hysterectomy
- Author
-
LASSEN, PERNILLE DANNESKIOLD, MOELLER-LARSEN, HEDVIG, and DE NULLY, PIA
- Published
- 2012
- Full Text
- View/download PDF
18. Distant metastases in squamous cell carcinoma of the pharynx and larynx: a population-based DAHANCA study.
- Author
-
Kjems, Julie, Zukauskaite, Ruta, Johansen, Jørgen, Eriksen, Jesper Grau, Lassen, Pernille, Andersen, Elo, Andersen, Maria, Farhadi, Mohammad, Overgaard, Jens, Vogelius, Ivan R., and Friborg, Jeppe
- Subjects
CONFIDENCE intervals ,LARYNGEAL tumors ,METASTASIS ,HEAD & neck cancer ,DISEASE incidence ,PHARYNX tumors ,DESCRIPTIVE statistics ,ODDS ratio ,SQUAMOUS cell carcinoma - Abstract
In head and neck cancer, distant metastases may be present at diagnosis (M1) or occur after treatment (DM). It is unknown whether M1 and DM follow the same clinical development and share prognosis, as population-based studies regarding outcomes are scarce. Therefore, we investigated the incidence, location of metastases and overall survival of patients with M1 and DM. Patients diagnosed with squamous cell carcinoma of the pharynx and larynx in Denmark 2008–2017 were identified in the Danish Head and Neck Cancer Group (DAHANCA) database. We identified 7300 patients, of whom 197 (3%) had M1 and 498 (8%) developed DM during follow-up. The 5-year cumulative incidence of DM was 8%. 1- and 2-year overall survival for DM (27% and 13%) vs. M1 (28% and 9%) were equally poor. There was no significant difference in location of metastases for M1 and DM and the most frequently involved organs were lungs, bone, lymph nodes and liver, in descending order. In oropharyngeal squamous cell carcinomas, the location of metastases did not differ by p16-status. For p16-positive patients, 21% of DM occurred later than three years of follow-up compared to 7% of p16-negative patients. Incidence, location of metastases and prognosis of primary metastatic (M1) or post-treatment metastatic (DM) disease in pharyngeal and laryngeal squamous cell carcinoma are similar in this register-based study [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. Current role of human papillomavirus in head and neck oncology
- Author
-
Lassen, Pernille
- Published
- 2013
- Full Text
- View/download PDF
20. Treatment outcomes and survival following definitive (chemo) radiotherapy in HPV+ oropharynx cancer: Large scale comparison of two population-based cohorts
- Author
-
Lassen, Pernille, Huang, Shao Hui, Su, Jie, O'sullivan, Brian, Andersen, Maria, Primdahl, Hanne, Johansen, Joergen, Kristensen, Claus Andrup, Andersen, Elo, Waldron, John, Bratman, Scott Victor, Ringash, Jolie, Spreafico, Anna, Xu, Wei, and Overgaard, Jens
- Published
- 2021
- Full Text
- View/download PDF
21. Characterization and radiosensitivity of HPV-related oropharyngeal squamous cell carcinoma patient-derived xenografts.
- Author
-
Lilja-Fischer, Jacob Kinggaard, Ulhøi, Benedicte Parm, Alsner, Jan, Stougaard, Magnus, Thomsen, Mette Skovhus, Busk, Morten, Lassen, Pernille, Steiniche, Torben, Nielsen, Viveque Egsgaard, and Overgaard, Jens
- Subjects
CANCER treatment ,ANIMAL experimentation ,HYPOXEMIA ,BIOPSY ,CELL receptors ,GENE expression ,IMMUNOHISTOCHEMISTRY ,MICE ,GENETIC mutation ,PAPILLOMAVIRUS diseases ,RADIOTHERAPY ,SQUAMOUS cell carcinoma ,STEM cells ,TUMOR markers ,XENOGRAFTS ,SEQUENCE analysis ,OROPHARYNGEAL cancer ,IN vivo studies - Abstract
Background: Oropharyngeal squamous cell carcinomas (OPSCC) are rising rapidly in incidence due to Human Papillomavirus (HPV) and/or tobacco smoking. Prognosis is better for patients with HPV-positive disease, but may also be influenced by tobacco smoking and other factors. There is a need to individualize treatment to minimize morbidity and improve prognosis. Patient-derived xenografts (PDX) is an emerging pre-clinical research model that may more accurately reflect the human disease, and is an attractive platform to study disease biology and develop treatments and biomarkers. In this study we describe the establishment of PDX models, compare PDX tumors to the human original, and assess the suitability of this model for radiotherapy research and biomarker development. Material and methods: Tumor biopsies from 34 patients with previously untreated OPSCC were implanted in immunodeficient mice, giving rise to 12 squamous cell carcinoma PDX models (7 HPV+, 5 HPV-). Primary and PDX tumors were characterized extensively, examining histology, immunohistochemistry, cancer gene sequencing and gene expression analysis. Radiosensitivity was assessed in vivo in a growth delay assay. Results: Established PDX models maintained histological and immunohistochemical characteristics as well as HPV-status of the primary tumor. Important cancer driver gene mutations, e.g., in TP53, PIK3CA and others, were preserved. Gene expression related to cancer stem cell markers and gene expression subtype were preserved, while gene expression related to hypoxia and immune response differed. Radiosensitivity studies showed high concordance with clinical observations. Conclusion: PDX from OPSCC preserves important molecular characteristics of the human primary tumor. Radiosensitivity were in accordance with clinically observed treatment response. The PDX model is a clinically relevant surrogate model of head and neck cancer. Perspectives include increased understanding of disease biology, which could lead to development of novel treatments and biomarkers. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
22. Correlation and prognostic impact of human papilloma virus and p16-expression in advanced hypopharynx and larynx cancer treated with definitive radiotherapy.
- Author
-
Lassen, Pernille, Schou, Marie, Overgaard, Jens, and Alsner, Jan
- Subjects
- *
PAPILLOMAVIRUSES , *HYPOPHARYNX ,LARYNGEAL tumors - Abstract
The article focuses on correlation and prognostic impact of human papilloma virus and p16-expression in advanced hypopharynx and larynx cancer treated with definitive radiotherapy. Topics include the human papilloma virus (HPV) is a well-established aetiological factor in oropharynx cancer (OPC), the global variation in the incidence of HPV plus OPC is considerable, and the countries with high age standardized incidence rates of the disease are located in Northern America and Europe.
- Published
- 2021
- Full Text
- View/download PDF
23. Expression of EGFR and HPV-associated p16 in head and neck cancer: correlation and influence on prognosis after radiotherapy in 1088 patients from the randomised DAHANCA 5, 6 & 7 trials
- Author
-
Lassen, Pernille, Eriksen, Jesper Grau, Tramm, Trine, Hamilton-Dutoit, Stephen Jacques, Alsner, Jan, and Overgaard, Jens
- Abstract
Background: Expression of p16 is highly correlated to infection with Human Papillomavirus in squamous cell carcinoma of the head and neck (HNSCC). Previous reports have demonstrated an inverse correlation between expression of epidermal growth factor receptor (EGFR) and p16 in HNSCC. The aim of this study was to examine the correlation between EGFR and p16 and to asses their influence on response to radiotherapy (RT) and survival in a large cohort of HNSCC patients treated with RT alone in the randomised DAHANCA 5, 6& 7 trials.Material and Methods: Between January 1986 and December 1999 The Danish Head and Neck Cancer group (DAHANCA) conducted the nationwide DAHANCA 5, 6& 7 randomised trials, focusing on overcoming the disadvantages of tumour cell hypoxia and accelerated tumour cell proliferation in relation to RT. In the present study 1088 pre-treatment tumour tissues from patients in these trials were examined by immunohistochemistry for EGFR-expression (high/low) and p16 status (pos/neg).Results: In total 258 of 1088 (24%) tumours were p16pos and 885 (81%) had high EGFR-expression. The correlation between EGFR and p16 was found to be inverse with p16pos tumours tending to have lower EGFR-expression (27%) compared to p16neg tumours (16%, pppp
- Published
- 2009
24. Human Papilloma Virus as a Biomarker for Personalized Head and Neck Cancer Radiotherapy.
- Author
-
Eriksen, Jesper Grau and Lassen, Pernille
- Published
- 2016
- Full Text
- View/download PDF
25. 3-dimensional versus conventional laparoscopy for benign hysterectomy: protocol for a randomized clinical trial.
- Author
-
Hoffmann, Elise, Bennich, Gitte, Larsen, Christian Rifbjerg, Lindschou, Jannie, Jakobsen, Janus Christian, and Lassen, Pernille Danneskiold
- Subjects
LAPAROSCOPY ,SURGERY ,HYSTERECTOMY ,POSTOPERATIVE pain ,QUALITY of life ,LENGTH of stay in hospitals ,TREATMENT effectiveness ,COMPARATIVE studies ,HEALTH surveys ,RESEARCH methodology ,MEDICAL cooperation ,MEDICAL protocols ,QUESTIONNAIRES ,RESEARCH ,EVALUATION research ,RANDOMIZED controlled trials - Abstract
Background: Hysterectomy is one of the most common surgical procedures for women of reproductive age. Laparoscopy was introduced in the 1990es and is today one of the recommended routes of surgery. A recent observational study showed that operative time for hysterectomy was significantly lower for 3-dimensional compared to conventional laparoscopy. Complication rates were similar for the two groups. No other observational studies or randomized clinical trials have compared 3-dimensional to conventional laparoscopy in patients undergoing total hysterectomy for benign disease. The objective of the study is to determine if 3D laparoscopy gives better quality of life, less postoperative pain, less per- and postoperative complications, shorter operative time, or a shorter stay in hospital and a faster return to work or normal life, compared to conventional laparoscopy for benign hysterectomy.Methods/design: The design is a randomised multicentre clinical trial. Participants will be 400 women referred for laparoscopic hysterectomy for benign indications. Patients will be randomized to 3-dimensional or conventional laparoscopic hysterectomy. Operative procedures will follow the same principles and the same standard whether the surgeon's vision is 3-dimensional or conventional laparoscopy. Primary outcomes will be the impact of surgery on quality of life, assessed by the SF 36 questionnaire, and postoperative pain, assessed by a Visual Analogue scale for pain measurement. With a standard deviation of 12 points on SF 36 questionnaire, a risk of type I error of 3.3% and a risk of type II error of 10% a sample size of 190 patients in each arm of the trial is needed. Secondarily, we will investigate operative time, time to return to work, length of hospital stay, and - and postoperative complications.Discussion: This trial will be the first randomized clinical trial investigating the potential clinical benefits and harms of 3-dimensional compared to conventional laparoscopy. The results may provide more evidence regarding the future place of 3-dimensional laparoscopy in the range of endoscopic approaches for benign hysterectomy.Trial Registration: This study is registered at ClinicalTrial.gov: NCT02610985 November 16th 2015. November 2015. The regional Ethical committee approved it on the 12. November 2015, approval number: SJ-498. Data handling was approved by the Danish Data Protection Agency: REG-109-2015 on the 13. November 2015. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
26. Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? - Results from the randomized DAHANCA 5 and 7 trials.
- Author
-
Hoff, Camilla Molich, Lassen, Pernille, Eriksen, Jesper Grau, Hansen, Hanne Sand, Specht, Lena, Overgaard, Marie, Grau, Cai, Johansen, Jørgen, Bentzen, Jens, Andersen, Lisbeth, Evensen, Jan F., and Overgaard, Jens
- Subjects
- *
BLOOD transfusion , *CONFIDENCE intervals , *HEMOGLOBINS , *MULTIVARIATE analysis , *HEALTH outcome assessment , *STATISTICAL sampling , *SQUAMOUS cell carcinoma , *STATISTICS , *SURVIVAL analysis (Biometry) , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *PROPORTIONAL hazards models , *DATA analysis software - Abstract
Background. Patients with head and neck squamous cell carcinoma (HNSCC) and a low level of hemoglobin often have a poor response to radiation that may be related to hypoxia-induced radioresistance. We have previously published the importance of hemoglobin level and the effect of transfusion by the results from the randomized DAHANCA 5 trial, including 414 patients in the analysis. Aim of the current analysis was to gain additional power by adding patients from the continued subrandomization in the DAHANCA 7 trial, now including a total of almost 1200 patients. Material and methods. Patients were randomized to treatment in the DAHANCA 5 and 7 study (nimorazole vs. placebo and five fx/week vs. six fx/week), and in addition, patients with 'low' pre-irradiation hemoglobin values (females <13 g/dl; males <14.5 g/dl) were subrandomized to plus or minus transfusion. Transfusion was given with packed red blood cells with the aim to achieve a hemoglobin level in the 'high' value range. Results. A total of 1166 patients were included, 701 patients had high hemoglobin levels and 465 had low hemoglobin levels. Among the low hemoglobin patients, 235 were randomized to receive transfusion. Patient characteristics and treatment arms were well balanced. In the majority of patients, transfusion resulted in increased hemoglobin levels although this decreased slightly throughout treatment as in the non-transfused patients. Overall, the patients with low hemoglobin level had a significant reduced probability of locoregional control, disease-specific and overall survival. In the low hemoglobin group, transfusion did not improve the outcome in locoregional control, disease-specific or overall survival. In multivariate analyses, HPV/p16 status, T and N classification were significant factors for all outcome measures, whereas there was no significant influence of transfusion or hemoglobin level on endpoints. Conclusion. Transfusion prior to and during radiation treatment did not improve the outcome in patients with HNSCC and low hemoglobin values, but may have a negative impact on survival. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
27. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: Evaluation of the randomised DAHANCA 6&7 trial
- Author
-
Lassen, Pernille, Eriksen, Jesper G., Krogdahl, Annelise, Therkildsen, Marianne Hamilton, Ulhøi, Benedicte P., Overgaard, Marie, Specht, Lena, Andersen, Elo, Johansen, Jørgen, Andersen, Lisbeth J., Grau, Cai, and Overgaard, Jens
- Subjects
- *
GENE expression , *RADIOTHERAPY , *HEAD & neck cancer treatment , *RANDOMIZED controlled trials , *PAPILLOMAVIRUSES , *IMMUNOHISTOCHEMISTRY , *TUMOR treatment - Abstract
Abstract: Background and purpose: Tumour HPV-positivity is a favourable prognostic factor in the radiotherapy of HNSCC, but the optimal radiotherapy regimen for HPV-positive HNSCC is not yet defined. Reducing overall treatment time is known to improve outcome in the radiotherapy of HNSCC as was also demonstrated in the randomised DAHANCA 6&7 trial. We aimed to assess the influence of tumour HPV-status, expressed by p16, on the response to accelerated fractionated radiotherapy in HNSCC through evaluation of the DAHANCA 6&7 trial. Materials and methods: Immunohistochemical detection of HPV-associated p16-expression was performed on FFPE-pre-treatment tumour-tissues from 794 patients enrolled in the DAHANCA 6&7 trial. The influence of tumour p16-status on loco-regional tumour control and survival as a function of fractionation schedule (5Fx/week vs 6Fx/week) was evaluated 5years after the completion of radiotherapy. Results: The significant and independent prognostic value of tumour p16-positivity in HNSCC radiotherapy was confirmed, with adjusted hazard ratios (HR) of 0.58 [0.43–0.78], 0.47 [0.33–0.67] and 0.54 [0.42–0.68] for loco-regional control, disease-specific and overall survival, respectively. Accelerated radiotherapy significantly improved loco-regional tumour control compared to conventional radiotherapy, adjusted HR: 0.73 [0.59–0.92] and the benefit of the 6Fx/week regimen was observed both in p16-positive (HR: 0.56 [0.33–0.96]) as well as in p16-negative tumours (HR: 0.77 [0.60–0.99]). Disease-specific survival was also significantly improved with accelerated radiotherapy in the group of p16-positive tumours (adjusted HR: 0.43 [0.22–0.82]). Conclusion: Accelerated radiotherapy significantly improves outcome in HNSCC compared to conventional fractionation. The observed benefit is independent of tumour p16-status and the use of a moderately accelerated radiotherapy regimen seems advantageous also for HPV/p16-positive HNSCC. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
28. Fetal goiter and bilateral ovarian cysts.
- Author
-
Lassen, Pernille D., Sundberg, Karin, Juul, Anders, and Skibsted, Lillian
- Subjects
- *
GOITER , *CYSTS (Pathology) , *MEDICAL imaging systems , *PRENATAL diagnosis , *TUMORS - Abstract
A unique case of fetal goiter accompanied by bilateral ovarian cysts in a mother treated with methimazole for Graves'disease is reported. The abnormal findings were detected by ultrasound at 31 weeks of gestation. Umbilical fetal blood sampling revealed elevated serum TSH, normal concentrations of free T 4 , normal FSH and LH and high concentrations of E 2 . A series of weekly amniocenteses and intra-amniotic injections of levothyroxine was initiated, along with a reduction of the mother's methimazole dosage. The level of TSH in amniotic fluid was initially high, but was considerably reduced by each injection and followed by a gradual reduction of fetal goiter as well as the left ovarian cyst. The right cyst ruptured spontaneously. At 36 weeks + 4 days, the patient underwent elective caesarean section and gave birth to a female, weighing 2,880 g with 1- and 5-min Apgar scores of 10. The thyroid gland appeared normal in size, and cord blood TSH and free T 4 were both within normal limits. At ultrasound control 6 days later, the right ovarian cyst was not visible, while the left cyst was still present. Thus, our report supports previous findings that fetal goiter can be treated successfully with intra-amniotic injection of levothyroxine.More importantly, it shows that fetal hypothyroidism with elevated levels of TSH can be accompanied by ovarian cysts,suggesting interference between thyreotropic and gonadotropic hormones. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
29. Do all patients with head and neck cancer benefit from radiotherapy and concurrent cetuximab?
- Author
-
Eriksen, Jesper Grau, Lassen, Pernille, and Overgaard, Jens
- Published
- 2010
- Full Text
- View/download PDF
30. 191 Dose prescription variability in Oropharynx Cancer Radiotherapy.
- Author
-
Hansen, Christian R, Tadic, Tony, McNiven, Andrea, Petersen, Jens, Manju, Sharma, Price, Gareth, Naser, Mohamed A, Lassen, Pernille, Overgaard, Jens, McDowell, Lachlan, Fuller, Clifton David, Thomsen, David, Yom, Sue S, Johansen, J⊘rgen, Friborg, Jeppe, and Hope, Andrew
- Subjects
- *
CANCER radiotherapy , *RADIOTHERAPY treatment planning , *OROPHARYNX , *DRUG dosage , *MEDICAL prescriptions - Abstract
Radiotherapy treatment planning hinges on a critical factor: the prescribed dose. Surprisingly, no consistent, standardised global approach to interpreting this prescription exists. This study aimed to examine and illustrate the variations in prescribed doses for the same treatment across North European and North American centres. The study analysed consecutively treated oropharynx cancer patients from six globally recognised radiotherapy departments. The criteria for inclusion encompassed curative IMRT or VMAT radiotherapy administered in 2017 or later. These centres were divided into three North American and three North European centres. Dose-volume histogram (DVH) data were extracted from the local treatment planning system for the Gross Tumour Volume (GTV), the high-dose Clinical Target Volume (CTV), and Planning Target Volume (PTV) for each patient. The DVH was sampled in 1 cGy dose bins across the 0 to 100 Gy range. All DVHs were scaled to a standard prescription of 70 Gy delivered in 35 fractions to facilitate straightforward comparisons across centres. No biological corrections were applied. For the three target volumes (GTV, CTV, PTV), we extracted and compared metrics such as D95% (Dose to 95% of the volume), D98%, D99%, V95% (Volume receiving 95% of the prescription dose), V105%, and V107%. We visually compared these metrics and conducted statistical testing using the Mann-Whitney U-test. Our study encompassed 1,375 patients treated across six centres, revealing a spectrum of 38 different dose prescriptions, ranging from 55 Gy in 20 to 70 Gy in 35 fractions. When normalised to 70 Gy, the median mean CTV dose exhibited a 4% difference, ranging from 70.12 Gy to 72.93 Gy across centres. Notably, the three European centres showed a high consistency, deviating by only 0.4%, while the three North American centres showed a slight variation within 2%. Figure 1 presents the mean CTV dose and the D98% boxplots. The interquartile range (IQR) for the mean CTV dose from 0.17 Gy to 1.22 Gy, with European centres showing the smallest IQR. [Display omitted] Examining the near-minimum CTV doses (D98% of CTV), we observed a range from 68.65 Gy to 70.96 Gy, with an IQR from 0.30 Gy to 1.15 Gy. A scatter plot of CTV mean dose against CTV D98% revealed distinct clusters for each of the six centres (Figure 2). Notably, the European centres cluster more densely compared to the North American centres. [Display omitted] The variation in prescribed doses for the same treatment regimen poses a significant challenge. Clinical interpretation of 70 Gy varies widely between centres and is influenced by each centre's individual experience, which, in turn, impacts the interpretation of published results. European centres primarily adhere to the ICRU dose prescription, targeting the median CTV dose. Conversely, North American centres tend to prescribe based on the minimum dose to the CTV or, in some cases, the PTV, as outlined in various RTOG protocols. Our study underscores that prescribing a dose of 70 Gy in 35 fractions for standard oropharynx cancer patients results in substantial variations in mean and near-minimum CTV doses. These dose prescription discrepancies significantly impact the interpretation of clinical trial outcomes comparison. Furthermore, this significant dosimetric variability has important implications for dose de-escalation strategies for HPV+ oropharynx cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Scoring and classification of oropharyngeal carcinoma based on HPV-related p16-expression
- Author
-
Lassen, Pernille and Overgaard, Jens
- Published
- 2012
- Full Text
- View/download PDF
32. TiCPG - a strategy for the simultaneous enrichment of reversibly modified cysteine peptides, phosphopeptides, and sialylated N-Glycopeptides to study cytokines stimulated beta-cells.
- Author
-
Huang, Honggang, Drici, Lylia, Lassen, Pernille S., Palmisano, Giuseppe, and Larsen, Martin R.
- Subjects
- *
PHOSPHOPEPTIDES , *PANCREATIC beta cells , *CELL communication , *BIOLOGICAL systems , *PEPTIDES - Abstract
Diverse post-translational modifications (PTMs) regulate protein function and interaction to fine-tune biological processes. Reversible phosphorylation, cysteines (Cys) modifications, and N-linked glycosylation are all essentially involved in cellular signaling pathways, such as those initiated by the action of pro-inflammatory cytokines, which can induce pancreatic β-cell death and diabetes. Here we have developed a novel strategy for the simultaneous and comprehensive characterization of the proteome and three PTMs including reversibly modified Cysteines (rmCys), phosphorylation, and sialylated N-linked glycosylation from low amount of sample material. This strategy, termed TiCPG, is based on a combination of chemical labeling and titanium dioxide (TiO 2) chromatography. We applied the TiCPG strategy to study the proteome and the three PTMs changes in β-cells subject to pro-inflammatory cytokines stimulation. It enabled quantitative analysis of 8346 rmCys sites, 10,321 phosphosites and 962 sialylated N-glycosites from 5496 proteins. Significant regulation was found on 100 proteins at the expression level, while 3020 PTM peptide isoforms from 1468 proteins were significantly regulated. The three PTMs were involved in cytokine mediated β-cell apoptosis, such as the NFκB and the inducible NO synthase signaling pathways. Overall, the TiCPG strategy is a cheap, straightforward, and powerful tool for studies targeting the three PTMs described above. The present study presents a fast and easy method for quantitative assessment of the proteome and three PTMs from minimal amount of sample material. This simple method provides comprehensive and significant knowledge on biological systems and cellular signaling with relatively low analysis time, suitable for younger researchers and researchers that do not have direct access to LC-MSMS in their laboratories. From sub-milligram amount of material, we were able to map known cellular signaling events of proinflammatory cytokine effect on beta-cells and to discover novel PTMs involved in several known signaling pathways. [Display omitted] • Presentation of a simple method to assess the proteome and three PTMs from low amount of biological material. • The TiCPG method is used to study changes in the three PTMs in INS-1E beta cells upon proinflammatory cytokine stimulation. • Using TiCPG to study the interplay between phosphorylation and reversibly modified cysteines in a biological system. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. EFFECT OF HPV ON TREATMENT OUTCOME AND SURVIVAL IN OROPHARYNGEAL CARCINOMA-A SUBGROUP ANALYSIS OF THE RANDOMIZED DAHANCA 5&7 TRIALS.
- Author
-
Lassen, Pernille, Eriksen, Jesper G., Tramm, Trine, Alsner, Jan, Dutoit, Stephen H., and Overgaard, Jens
- Subjects
- *
PAPILLOMAVIRUSES , *PHARYNGEAL cancer , *PROGNOSIS , *RADIOTHERAPY , *DNA - Abstract
Objectives: To demonstrate the correlation between p16 overexpression and HPV in oropharyngeal carcinoma and to evaluate the prognostic impact of p16 status in a prospectively analyzed cohort of Danish oropharyngeal cancer patients. Materials and Methods: 32 tunsillar carcinomas were arranged in a Tissue Micro Array and evaluated by IHC for p16 overexpression. HPV-16 DNA detection was done by in situ hybridization. Between 1986 and 1999 The Danish Head and Neck Cancer group conducted the DAHANCA 5&7 randomized trials. In the present study 335 pre-treatment oropharyngeal tumour blocks from patients enrolled in these trials were evaluated by IHC for p16 status. Results: 20 of 32 (62.5%) tonsillar carcinomas were HPV-16 positive and 19 of these were p16 positive (sensitivity: 0.95). 12 turnouts were H PV-16 negative and 10 of these were p16 negative (specificity: 0.83). The two markers matched in 29 of 32 (90%) of the tumours. In total 135 of 335 (40%) oropharyngeal tumours were p16 positive. In univariate analysis, loco-regional turnout control was significantly improved for p16 positive tumours with 5-year actuarial values of 67% versus 36%, p < 0.0001. A similar beneficial outcome for p16 positive tumours was observed for cancer specific survival (69% versus 35%, p < 0.0001) and overall survival (54% versus 18%, p < 0.0001). In multivariate analysis p16 overexpression remained a very strong independent prognostic factor for loco-regional tumour control [OR: 0.35 (95% C.I. 0.24-0.51)], cancer specific death [OR: 0.28 (0.18-0.42)] and overall death [OR: 0.33 (0.24 0.46)] respectively. p16 was an even stronger prognostic factor related to these outcomes than T-stage and Nodal-status. Conclusions: p16 overexpression proved to be the strongest independent prognostic factor related to survival and loco-regional tumour control in our study and so we conclude that HPV infection is significantly correlated to improved prognosis and response to radiotherapy in oropharyngeal cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2008
34. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck
- Author
-
Toustrup, Kasper, Sørensen, Brita Singers, Lassen, Pernille, Wiuf, Carsten, Alsner, Jan, and Overgaard, Jens
- Subjects
- *
SQUAMOUS cell carcinoma , *CANCER treatment , *HEAD & neck cancer treatment , *CANCER radiotherapy , *GENE expression , *HYPOXEMIA , *PREDICTIVE validity - Abstract
Abstract: Purpose: To validate the predictive impact of a hypoxia gene expression classifier in identifying patients with head and neck squamous cell carcinoma (HNSCC) having benefit from hypoxic modification of radiotherapy. Patients and methods: Gene expressions were quantified from formalin-fixed, paraffin-embedded tumour biopsies of 323 HNSCC patients randomized for placebo or nimorazole in conjunction with radiotherapy in the DAHANCA 5 study. Tumours were classified as either “more” or “less” hypoxic with a classifier constituting of 15 hypoxia responsive genes. The predictive impact was evaluated by analysing the response to nimorazole vs. placebo in terms of loco-regional tumour control (LRC) and disease-specific survival (DSS) in the two classified groups. Results: Hundred and fourteen patients (35%) were classified as having “more” hypoxic tumours. These patients had a significant benefit of hypoxic modification with nimorazole compared with placebo in terms of LRC (5-year actuarial values 49% vs. 18%; p =0.001) and DSS (48% vs. 30%; p =0.04). “Less” hypoxic tumours had no significant effect of hypoxic modification (LRC: 50% vs. 44%; p =0.39, DSS: 57% vs. 51%; p =0.49) and generally an outcome, which was similar to “more” hypoxic tumours treated with nimorazole. In contrast to HPV-negative tumours, HPV-positive tumours had a substantially better outcome in response to radiotherapy, which was irrespective of hypoxic modification. Conclusions: A predictive 15-gene hypoxia classifier could identify patients associated with improved outcome after combining radiotherapy with hypoxic modification and underlines the relevance of such therapy. The impact of the classifier was limited to HPV-negative tumours. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
35. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial
- Author
-
Mortensen, Lise Saksø, Johansen, Jørgen, Kallehauge, Jesper, Primdahl, Hanne, Busk, Morten, Lassen, Pernille, Alsner, Jan, Sørensen, Brita S., Toustrup, Kasper, Jakobsen, Steen, Petersen, Jørgen, Petersen, Henrik, Theil, Jørn, Nordsmark, Marianne, and Overgaard, Jens
- Subjects
- *
SQUAMOUS cell carcinoma , *POSITRON emission tomography , *CANCER radiotherapy , *TOMOGRAPHY , *CLINICAL trials , *HEAD & neck cancer treatment - Abstract
Abstract: Purpose: Hypoxia is a cause of resistance to radiotherapy, especially in patients with head and neck squamous cell carcinoma (HNSCC). The purpose of this study was to evaluate 18F-fluoroazomycin arabinoside (FAZA) positron emission tomography (PET)/computed tomography (CT) hypoxia imaging as a prognostic factor in HNSCC patients receiving radiotherapy. Material and methods: Forty patients with HNSCC treated with radiotherapy (66–76Gy) were included. Static FAZA PET/CT imaging 2h post injection was conducted prior to irradiation. The hypoxic volume (HV) was delineated using a tumor-to-muscle value ⩾1.4. In 13 patients, a repetitive FAZA PET/CT scan was conducted during the radiotherapy treatment. Results: A hypoxic volume could be identified in 25 (63%) of the 40 tumors. FAZA PET HV varied considerably with a range from 0.0 to 30.9 (median: 0.3) cm3. The Tmax/Mmed ranged from 1.1 to 2.9 (median: 1.5). The distribution of hypoxia among the Human Papillomavirus (HPV) positive (12/16) and negative (13/24) tumors was not significant different. In the FAZA PET/CT scans performed during radiotherapy, hypoxia could be detected in six of the 13 patients. For these six patients the location of HV remained stable in location during radiotherapy treatment, though the size of the HV decreased. In 30 patients a positive correlation was detected between maximum FAZA uptake in the primary tumor and the lymph node. During a median follow up of 19months a significant difference in disease free survival rate with 93% for patients with non hypoxic tumors and 60% for patients with hypoxic tumors could be detected. Conclusion: This study emphasizes the role of FAZA PET/CT imaging as a suitable assay with prognostic potential for detection of hypoxia in HNSCC. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
36. Association of Smoking, Comorbidity, Clinical Stage, and Treatment Intent With Socioeconomic Differences in Survival After Oropharyngeal Squamous Cell Carcinoma in Denmark.
- Author
-
Olsen MH, Frederiksen K, Lassen P, Rotbøl C, Kjaer TK, Johansen J, Primdahl H, Andersen E, Kristensen CA, Andersen M, Farhadi M, Overgaard J, and Dalton SO
- Subjects
- Humans, Female, Aged, 80 and over, Middle Aged, Squamous Cell Carcinoma of Head and Neck, Cohort Studies, Smoking epidemiology, Papillomavirus Infections, Head and Neck Neoplasms
- Abstract
Importance: The socioeconomic gap in survival after cancer is pronounced among patients with head and neck cancer. Understanding the mechanisms of this gap is crucial to target intervention strategies., Objective: To investigate socioeconomic differences in survival after oropharyngeal squamous cell carcinoma (OPSCC) according to human papillomavirus (HPV) status and the extent to which smoking, comorbidity, clinical stage, and treatment intent explain the survival gap., Design, Setting, and Participants: This nationwide, population-based cohort study was based on prospectively collected information on all patients with a diagnosis of OPSCC from the Danish Head and Neck Cancer Group database and administrative registries. The study included 4600 patients born in 1921 or later, aged 30 years or older, and residing in Denmark 1 year prior to OPSCC diagnosis. Patients with missing information (547 [12%]) were excluded. Patients were diagnosed between January 1, 2008, and December 31, 2019, and followed up until December 31, 2021. Data were analyzed from June 6 to October 4, 2022., Exposure: Socioeconomic position (educational level, disposable income, or cohabiting status)., Main Outcomes and Measures: Socioeconomic differences in 5-year overall survival were estimated in Cox proportional hazards regression models by HPV status. The indirect effect and proportion mediated by smoking, comorbidity, clinical stage, and treatment intent were estimated based on a counterfactual approach., Results: The analyzed cohort comprised 4053 patients (1045 women [26%] and 3008 men [74%]). The median age was 61 years (IQR, 55-68 years), and 2563 patients (63%) had HPV-positive OPSCC while 1490 patients (37%) had HPV-negative OPSCC. The 5-year standardized overall survival was 10% to 15% lower among patients with a lower educational level, with low disposable income, or who were living alone (patients with HPV-positive OPSCC, 68%-71%; patients with HPV-negative OPSCC, 31%-34%) than patients with a higher educational level, high disposable income, or a cohabiting partner (patients with HPV-positive OPSCC, 81%-86%; patients with HPV-negative OPSCC, 43%-46%). Among patients with HPV-positive OPSCC, a considerable part of this survival gap was estimated to be associated with differences in smoking (27%-48%), comorbidity (10%-19%), clinical stage (8%-19%), and treatment intent (16%-28%). Among those with HPV-negative OPSCC, comorbidity (12%-22%) and treatment intent (16%-42%) were the primary potential mediators., Conclusions and Relevance: This cohort study suggests that, regardless of HPV status, patients with low socioeconomic position had 10% to 15% lower 5-year overall survival than patients with high socioeconomic position. A substantial part of this survival gap was associated with differences in smoking, comorbidity, clinical stage, or treatment intent at diagnosis.
- Published
- 2022
- Full Text
- View/download PDF
37. TNFα affects CREB-mediated neuroprotective signaling pathways of synaptic plasticity in neurons as revealed by proteomics and phospho-proteomics.
- Author
-
Jensen P, Myhre CL, Lassen PS, Metaxas A, Khan AM, Lambertsen KL, Babcock AA, Finsen B, Larsen MR, and Kempf SJ
- Abstract
Neuroinflammation is a hallmark of Alzheimer's disease and TNFα as the main inducer of neuroinflammation has neurodegenerative but also pro-regenerative properties, however, the dose-dependent molecular changes on signaling pathway level are not fully understood. We performed quantitative proteomics and phospho-proteomics to target this point. In HT22 cells, we found that TNFα reduced mitochondrial signaling and inhibited mTOR protein translation signaling but also led to induction of neuroprotective MAPK-CREB signaling. Stimulation of human neurons with TNFα revealed similar cellular mechanisms. Moreover, a number of synaptic plasticity-associated genes were altered in their expression profile including CREB . SiRNA-mediated knockdown of CREB in human neurons prior to TNFα stimulation led to a reduced number of protein/phospho-protein hits compared to siRNA-mediated knockdown of CREB or TNFα stimulation alone and countermeasured the reduced CREB signaling. In vivo data of TNFα knockout mice showed that learning ability did not depend on TNFα per se but that TNFα was essential for preserving the learning ability after episodes of lipopolysaccharide-induced neuroinflammation. This may be based on modulation of CREB/CREB signaling as revealed by the in vitro / in vivo data. Our data show that several molecular targets and signaling pathways induced by TNFα in neurons resemble those seen in Alzheimer's disease pathology., Competing Interests: CONFLICTS OF INTEREST The authors declare no competing interests.
- Published
- 2017
- Full Text
- View/download PDF
38. Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography.
- Author
-
Huang H, Haar Petersen M, Ibañez-Vea M, Lassen PS, Larsen MR, and Palmisano G
- Subjects
- Chromatography, Liquid methods, Epidermal Growth Factor pharmacology, ErbB Receptors metabolism, HeLa Cells, Humans, Isotope Labeling, Organophosphonates chemistry, Phosphopeptides chemistry, Phosphorylation, Signal Transduction drug effects, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization methods, Titanium, Cysteine chemistry, Organophosphonates chemical synthesis, Peptides chemistry, Proteomics methods
- Abstract
Cysteine is a rare and conserved amino acid involved in most cellular functions. The thiol group of cysteine can be subjected to diverse oxidative modifications that regulate many physio-pathological states. In the present work, a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) was synthesized to selectively label cysteine-containing peptides (Cys peptides) followed by their enrichment with titanium dioxide (TiO
2 ) and subsequent mass spectrometric analysis. The CysPAT strategy was developed using a synthetic peptide, a standard protein and subsequently the strategy was applied to protein lysates from Hela cells, achieving high specificity and enrichment efficiency. In particular, for Cys proteome analysis, the method led to the identification of 7509 unique Cys peptides from 500 μg of HeLa cell lysate starting material. Furthermore, the method was developed to simultaneously enrich Cys peptides and phosphorylated peptides. This strategy was applied to SILAC labeled Hela cells subjected to 5 min epidermal growth factor (EGF) stimulation. In total, 10440 unique reversibly modified Cys peptides (3855 proteins) and 7339 unique phosphopeptides (2234 proteins) were simultaneously identified from 250 μg starting material. Significant regulation was observed in both phosphorylation and reversible Cys modification of proteins involved in EGFR signaling. Our data indicates that EGF stimulation can activate the well-known phosphorylation of EGFR and downstream signaling molecules, such as mitogen-activated protein kinases (MAPK1 and MAPK3), however, it also leads to substantial modulation of reversible cysteine modifications in numerous proteins. Several protein tyrosine phosphatases (PTPs) showed a reduction of the catalytic Cys site in the conserved putative phosphatase HC(X)5R motif indicating an activation and subsequent de-phosphorylation of proteins involved in the EGF signaling pathway. Overall, the CysPAT strategy is a straight forward, easy and promising method for studying redox proteomics and the simultaneous enrichment strategy offers an excellent solution for characterization of cross-talk between phosphorylation and redox induced reversible cysteine modifications., Competing Interests: A patent application has been filed on which HH, MRL and GP are listed as inventors., (© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.)- Published
- 2016
- Full Text
- View/download PDF
39. Human Papilloma Virus as a Biomarker for Personalized Head and Neck Cancer Radiotherapy.
- Author
-
Eriksen JG and Lassen P
- Subjects
- Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell virology, Chemoradiotherapy, Head and Neck Neoplasms drug therapy, Head and Neck Neoplasms virology, Host-Pathogen Interactions drug effects, Host-Pathogen Interactions radiation effects, Humans, Oncogene Proteins, Viral analysis, Papillomaviridae drug effects, Papillomaviridae physiology, Papillomavirus Infections drug therapy, Papillomavirus Infections virology, Prognosis, Carcinoma, Squamous Cell radiotherapy, Head and Neck Neoplasms radiotherapy, Papillomaviridae radiation effects, Papillomavirus Infections radiotherapy, Precision Medicine methods
- Abstract
A dramatic increase in the incidence of HPV-related oropharyngeal cancer has been reported in some parts of the western world over the past 30 years. They constitute a clinically distinct subgroup of cancers in terms of molecular biology, patient characteristics, and treatment outcome. This chapter describes the molecular characteristics, epidemiology, and demographics of the HPV-related head and neck cancers and discuss available methods to detect HPV-related tumours. The impact of HPV-related biomarkers in clinical studies on radiotherapy only, altered fractionation, modulation of hypoxia, and concurrent chemo- or bio-radiotherapy are reviewed as well as the perspectives of de-escalation and immune-modulation are discussed.
- Published
- 2016
- Full Text
- View/download PDF
40. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.
- Author
-
Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, and Overgaard J
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell metabolism, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell virology, Cohort Studies, Female, Follow-Up Studies, Head and Neck Neoplasms metabolism, Head and Neck Neoplasms mortality, Head and Neck Neoplasms virology, Humans, In Situ Hybridization, Male, Middle Aged, Neoplasm Staging, Papillomavirus Infections metabolism, Papillomavirus Infections mortality, Papillomavirus Infections virology, Placebos, Prognosis, Prospective Studies, Survival Rate, Treatment Outcome, Young Adult, Biomarkers, Tumor metabolism, Carcinoma, Squamous Cell radiotherapy, Cyclin-Dependent Kinase Inhibitor p16 metabolism, Head and Neck Neoplasms radiotherapy, Papillomaviridae isolation & purification, Papillomavirus Infections radiotherapy
- Abstract
Purpose: A subset of head and neck cancers is associated with the human papillomavirus (HPV). Viral infection is closely correlated with expression of p16(INK4A) in these tumors. We evaluated p16(INK4A) as a prognostic marker of treatment response and survival in a well-defined and prospectively collected cohort of patients treated solely with conventional radiotherapy in the Danish Head and Neck Cancer Group (DAHANCA) 5 trial., Patients and Methods: Immunohistochemical expression of p16(INK4A) was analyzed in pretreatment paraffin-embedded tumor blocks from 156 patients treated with conventional primary radiotherapy alone. The influence of p16(INK4A) status on locoregional tumor control, disease-specific survival, and overall survival after radiotherapy was evaluated., Results: p16(INK4A) positivity was found in 35 tumors (22%). Tumor-positivity for p16(INK4A) was significantly correlated with improved locoregional tumor control (5-year actuarial values 58% v 28%; P = .0005), improved disease-specific survival (72% v 34%; P = .0006), and improved overall survival (62% v 26%; P = .0003). In multivariate analysis, p16(INK4A) remained a strong independent prognostic factor for locoregional failure (hazard ratio [HR], 0.35; 95% CI, 0.19 to 0.64), disease-specific death (HR, 0.36; 95% CI, 0.20 to 0.64), and overall death (HR, 0.44; 95% CI, 0.28 to 0.68)., Conclusion: Expression of p16(INK4A) has a major impact on treatment response and survival in patients with head and neck cancer treated with conventional radiotherapy.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.